Ligand Pharmaceuticals
LGND
LGND
220 hedge funds and large institutions have $2.51B invested in Ligand Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 70 increasing their positions, 82 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 206 → 220 (+14)
1.44% less ownership
Funds ownership: 157.65% → 156.21% (-1.4%)
15% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 82
Holders
220
Holding in Top 10
4
Calls
$24.9M
Puts
$6.48M
Top Buyers
| 1 | +$8.36M | |
| 2 | +$6.56M | |
| 3 | +$5.48M | |
| 4 |
Goldman Sachs
New York
|
+$4.25M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$4.18M |
Top Sellers
| 1 | -$9.63M | |
| 2 | -$7.4M | |
| 3 | -$7.27M | |
| 4 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
-$7.01M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$5.37M |